MedTrace Logo

Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM

NCT02887625 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 410

Last updated 2016-09-02

No results posted yet for this study

Summary

To compare efficacy, safety and durability of combination therapy with pioglitazone plus GLP-1 RA versus basal bolus insulin in poorly controlled T2DM patients on metformin plus sulfonylurea

Conditions

Interventions

DRUG

Pioglitazone plus exenatide

pioglitazone will be started at 30 mg/day and bydureon at 2 mg/week

DRUG

insulin glargine and insulin aspart

the dose will be escalated to maintain HbA1c \<7.0%

Sponsors & Collaborators

  • Dr. Muhammad Abdulghani

    lead INDUSTRY

Principal Investigators

  • Amin Jayyousi, MD · HMC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • Qatar

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02887625 on ClinicalTrials.gov